Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 2, 2010, Pages 195-200

  Mokabberi, R ^a   Haftbaradaran, A ^a   Ravakhah, K ^a  

^a Huron Hospital   (United States)

Author keywords

Community acquired pneumonia; Doxycycline; Fluoroquinolone; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE; HYPERTENSIVE AGENT; LEVOFLOXACIN; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; FOLLOW UP; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPOTENSION; HYPOXIA; IMMUNE DEFICIENCY; INTUBATION; KIDNEY DISEASE; LABORATORY; LENGTH OF STAY; LIVER DISEASE; MALE; METHODOLOGY; NURSING HOME; PROSPECTIVE STUDY; RANDOMIZATION; SEPSIS; TREATMENT FAILURE; WARD;

ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DOXYCYCLINE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77749304165     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01073.x     Document Type: Article

References (16)

1. Riccioni G, Di Pietro V, Staniscia T et al. (2005) Community acquired pneumonia in internal medicine: a one-year retrospective study based on pneumonia severity index. International Immunopathology Pharmacology, 18, 575 586.
2. Niederman MS (2004) Review of treatment guidelines for community-acquired pneumonia. American Journal of Medicine, 117 (Suppl. 3A 51S 57S.
3. Bosker G (editor-in-chief) ASCAP (Antibiotic Selection for Community-Acquired Pneumonia) (2004) Panel Consensus Report and Treatment Recommendations: Hospital Medicine Consensus Reports. Thompson American Health Consultants, 1, 2004.
4. Green DS, San Pedro GS (2000) Empiric therapy of community-acquired pneumonia. Seminars in Respiratory Infection, 15, 227 233.
5. Mandell LA, Wunderink RG, Anzueto A et al. (2007) Infectious Diseases Society of America/American Thoracic Society Consensus Guideline on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Disease, 44, S27 S72.
6. Woodhead M, Blasi F, Ewig S et al. (2005) Guidelines for the management of adult lower respiratory tract infections. European Respiratory Journal, 26, 1138 1180.
7. British Thoracic Society Standards of Care Committee (2001) BTS guidelines for the management of community acquired pneumonia in adults. Thorax, 56 (Suppl. 4 iv 1 iv 64.
8. Gotfried MH, Dattani D, Riffer E et al. (2002) A controlled, double blind, multi center study comparing Clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clinical Therapeutics, 24, 736 751.
9. Scheld WM (2003) Maintaining fluroquinolon class efficacy review of influencing factors. Emerging Infectious Diseases, 9, 1 9 RK, Agastya G, Ailani RK et al. (1999) Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Archives of Internal Medicine, 159, 266 270.
10. Woolley RJ (1998) Doxycycline and community-acquired pneumonia. Letter to the Editor, February 1, 1998 - American Family Physician.
11. Shea KW, Cunha BA (1995) Doxycycline activity against Streptococcus pneumonia. Chest, 108, 1775 1776.
12. Cunha BA (1996) Community-acquired pneumonia. Cost-effective antimicrobial therapy. Postgraduate Medicine, 99, 109 122.
13. Niederman MS, McCombc JS, Unger AN, Kumar A, Popovian R (1998) The cost of treating community-acquired pneumonia. Clinical Therapeutics, 20, 820 837.
14. Mommeja-Marin H, Carbon C (1999) What is the place of fluoroquinolones in the treatment of community acquired respiratory tract infections? Drugs, 57, 851 853.
15. Heffelfinger JD, Dowell SF, Jorgensen JH et al. (2000) Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the DRUG-Resistant Streptococcus pneumoniae Therapeutic Working Group. Archives of Internal Medicine, 160, 1399 1408.
16. Plouffe JF, Breiman RF, Facklam RR (1996) Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA, 275, 194 195.